Article

Sucampo voluntarily suspends tacrolimus eye drops program

Sucampo Pharmaceuticals Inc., Bethesda, MD, said it has voluntarily suspended its tacrolimus eye drops development program due to FDA safety concerns about Protopic, a prescription cream for the treatment of atopic dermatitis. Protopic's active ingredient is tacrolimus.

Sucampo Pharmaceuticals Inc., Bethesda, MD, said it has voluntarily suspended its tacrolimus eye drops development program due to FDA safety concerns about Protopic, a prescription cream for the treatment of atopic dermatitis. Protopic's active ingredient is tacrolimus.

The company said it was developing tacrolimus eye drops for the treatment of dry eye syndrome under a license from Fujisawa Pharmaceutical Co. Ltd. (Japan) and had completed its phase II safety and efficacy research.

Even though the agent is not a topical ointment, Sucampo officials stressed that patient safety comes first. The company said in a prepared statement that it will consult with the FDA to determine if and when the dry eye program should resume.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.